Generali Asset Management SPA SGR Makes New Investment in Stryker Co. (NYSE:SYK)

Generali Asset Management SPA SGR bought a new position in Stryker Co. (NYSE:SYK) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 9,399 shares of the medical technology company’s stock, valued at approximately $3,384,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Kohmann Bosshard Financial Services LLC bought a new stake in shares of Stryker during the fourth quarter valued at approximately $25,000. Dunhill Financial LLC increased its holdings in shares of Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after acquiring an additional 37 shares in the last quarter. Rakuten Securities Inc. increased its holdings in shares of Stryker by 618.2% during the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock valued at $28,000 after acquiring an additional 68 shares in the last quarter. Centricity Wealth Management LLC bought a new stake in shares of Stryker during the fourth quarter valued at approximately $30,000. Finally, BankPlus Trust Department bought a new stake in shares of Stryker during the fourth quarter valued at approximately $33,000. Institutional investors own 77.09% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on SYK shares. Royal Bank of Canada upped their price target on Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a report on Wednesday, January 29th. JMP Securities reiterated a “market perform” rating on shares of Stryker in a report on Tuesday, February 18th. JPMorgan Chase & Co. upped their price target on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. Barclays upped their price target on Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. Finally, Stifel Nicolaus upped their price target on Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Five research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $421.90.

Stryker Stock Up 0.6 %

Shares of NYSE SYK opened at $378.06 on Thursday. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The business’s fifty day moving average price is $383.99 and its 200-day moving average price is $373.85. The stock has a market capitalization of $144.26 billion, a PE ratio of 48.72, a P/E/G ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the firm posted $3.46 EPS. On average, equities research analysts anticipate that Stryker Co. will post 13.47 EPS for the current year.

Stryker Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.89%. Stryker’s dividend payout ratio (DPR) is 43.30%.

Insider Buying and Selling

In related news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now owns 14,895 shares of the company’s stock, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their position. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.